Investing.com - Biomerieux reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomerieux announced earnings per share of €2.73 on revenue of €924.5M. Analysts polled by Investing.com anticipated EPS of €1.75 on revenue of €905.23M.
Biomerieux shares are down 17% from the beginning of the year and are trading at €87.56 , down-from-52-week-high.They are under-performing the FTSE 100 which is up 0.61% from the start of the year.
Biomerieux follows other major Healthcare sector earnings this month
Biomerieux's report follows an earnings beat by Sanofi on Friday, February 4, 2022, who reported EPS of €1.38 on revenue of €9.99B, compared to forecasts EPS of €1.34 on revenue of €10.31B.
Ipsen had beat expectations on Friday, February 11, 2022 with fourth quarter EPS of €7.76 on revenue of €791M, compared to forecast for EPS of €3.39 on revenue of €774.01M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar